Guadecitabine
Guadecitabine is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
34 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloid leukemia acute | D015470 | — | C92.0 | 5 | 7 | 2 | — | — | 11 |
| Leukemia | D007938 | — | C95 | 3 | 3 | 3 | — | — | 8 |
| Myelodysplastic syndromes | D009190 | — | D46 | 2 | 7 | 1 | — | — | 8 |
| Myeloid leukemia | D007951 | — | C92 | 3 | 2 | 2 | — | — | 6 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 1 | 3 | 1 | — | — | 4 |
| Preleukemia | D011289 | — | — | 2 | 3 | 1 | — | — | 4 |
| Syndrome | D013577 | — | — | 1 | 2 | 1 | — | — | 3 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 2 | 4 | — | — | — | 5 |
| Recurrence | D012008 | — | — | 2 | 2 | — | — | — | 3 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 3 | — | — | — | 3 |
| Colorectal neoplasms | D015179 | — | — | 3 | 2 | — | — | — | 3 |
| Lung neoplasms | D008175 | — | C34.90 | 2 | 1 | — | — | — | 3 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 1 | — | — | — | 2 |
| Melanoma | D008545 | — | — | 1 | 1 | — | — | — | 2 |
| Fallopian tube neoplasms | D005185 | — | — | 1 | 2 | — | — | — | 2 |
| Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | 1 | 2 | — | — | — | 2 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | 2 | — | — | — | 2 |
Show 15 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Germ cell and embryonal neoplasms | D009373 | — | — | 1 | — | — | — | — | 1 |
| Testicular neoplasms | D013736 | — | C62 | 1 | — | — | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
| Adenocarcinoma | D000230 | — | — | 1 | — | — | — | — | 1 |
| Cholangiocarcinoma | D018281 | — | C22.1 | 1 | — | — | — | — | 1 |
| Gallbladder neoplasms | D005706 | EFO_0004606 | C23 | 1 | — | — | — | — | 1 |
| Ductal carcinoma | D044584 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Guadecitabine |
| INN | guadecitabine |
| Description | Guadecitabine is a small molecule pharmaceutical. It is currently being investigated in clinical studies. |
| Classification | Small molecule |
| Drug class | nucleoside antiviral or antineoplastic agents, cytarabine or azarabine derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1ncn([C@H]2C[C@H](OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)C[C@@H]3O)[C@@H](CO)O2)c(=O)n1 |
Identifiers
| PDB | — |
| CAS-ID | 929901-49-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3544916 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 2KT4YN1DP7 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,088 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
85 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use